Anderson, K. G., Su, Y., Burnett, M. G., Bates, B. M., Suarez Gutierrez, M. L., Ruskin, S. L., . . . Greenberg, P. D. (2023). 803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer. Journal for immunotherapy of cancer, 11(Suppl 1), A902. https://doi.org/10.1136/jitc-2023-SITC2023.0803
Citace podle Chicago (17th ed.)Anderson, Kristin G., Yapeng Su, Madison G. Burnett, Breanna M. Bates, Magdalia L. Suarez Gutierrez, Susan L. Ruskin, Valentin Voillet, Raphael Gottardo, a Philip D. Greenberg. "803 Triple Checkpoint Blockade, but Not Anti-PD1 Alone, Enhances the Efficacy of Engineered Adoptive T Cell Therapy in Advanced Ovarian Cancer." Journal for Immunotherapy of Cancer 11, no. Suppl 1 (2023): A902. https://doi.org/10.1136/jitc-2023-SITC2023.0803.
Citace podle MLA (9th ed.)Anderson, Kristin G., et al. "803 Triple Checkpoint Blockade, but Not Anti-PD1 Alone, Enhances the Efficacy of Engineered Adoptive T Cell Therapy in Advanced Ovarian Cancer." Journal for Immunotherapy of Cancer, vol. 11, no. Suppl 1, 2023, p. A902, https://doi.org/10.1136/jitc-2023-SITC2023.0803.